牛牛AI助理已提取核心訊息
Bristol-Myers Squibb (BMY) has successfully completed its tender offer to acquire all outstanding shares of RayzeBio, Inc. for $62.50 per share in cash, amounting to approximately $4.1 billion. The offer, which expired on February 22, 2024, saw approximately 86% of RayzeBio's shares being validly tendered and not withdrawn. With the minimum condition for the tender offer satisfied, Bristol-Myers Squibb plans to promptly accept for payment all validly tendered shares on February 26, 2024. The acquisition will result in RayzeBio becoming a wholly owned subsidiary of Bristol-Myers Squibb, and its shares will be delisted from the Nasdaq Global Market. The merger is expected to be completed on the same day as the acceptance of the shares, without the need for a vote from RayzeBio's stockholders. Following the merger, Bristol-Myers Squibb intends to terminate the registration of RayzeBio's shares under the Exchange Act and suspend all of its reporting obligations as soon as practicable.
Bristol-Myers Squibb (BMY) has successfully completed its tender offer to acquire all outstanding shares of RayzeBio, Inc. for $62.50 per share in cash, amounting to approximately $4.1 billion. The offer, which expired on February 22, 2024, saw approximately 86% of RayzeBio's shares being validly tendered and not withdrawn. With the minimum condition for the tender offer satisfied, Bristol-Myers Squibb plans to promptly accept for payment all validly tendered shares on February 26, 2024. The acquisition will result in RayzeBio becoming a wholly owned subsidiary of Bristol-Myers Squibb, and its shares will be delisted from the Nasdaq Global Market. The merger is expected to be completed on the same day as the acceptance of the shares, without the need for a vote from RayzeBio's stockholders. Following the merger, Bristol-Myers Squibb intends to terminate the registration of RayzeBio's shares under the Exchange Act and suspend all of its reporting obligations as soon as practicable.
百時美施貴寶（BMY）成功完成了以每股62.50美元現金收購RayzeBio, Inc.所有已發行股份的要約，總額約爲41億美元。該要約於2024年2月22日到期，RayzeBio約有86％的股票進行了有效投標且未撤回。在滿足要約的最低條件後，百時美施貴寶計劃在2024年2月26日立即接受所有有效投標的股票付款。此次收購將使RayzeBio成爲百時美施貴寶的全資子公司，其股票將從納斯達克全球市場退市。合併預計將在接受股票的同一天完成，無需RayzeBio的股東投票。合併後，百時美施貴寶打算終止RayzeBio根據《交易法》註冊的股份，並儘快暫停其所有報告義務。
百時美施貴寶（BMY）成功完成了以每股62.50美元現金收購RayzeBio, Inc.所有已發行股份的要約，總額約爲41億美元。該要約於2024年2月22日到期，RayzeBio約有86％的股票進行了有效投標且未撤回。在滿足要約的最低條件後，百時美施貴寶計劃在2024年2月26日立即接受所有有效投標的股票付款。此次收購將使RayzeBio成爲百時美施貴寶的全資子公司，其股票將從納斯達克全球市場退市。合併預計將在接受股票的同一天完成，無需RayzeBio的股東投票。合併後，百時美施貴寶打算終止RayzeBio根據《交易法》註冊的股份，並儘快暫停其所有報告義務。
有用
沒用
